Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
82.69
-19.47 (-19.05%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Mar 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,536,169
Open
82.81
Bid (Size)
82.62 (200)
Ask (Size)
82.77 (300)
Prev. Close
102.16
Today's Range
79.52 - 85.50
52wk Range
81.20 - 124.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why BioNTech Stock Is Getting Crushed Today
↗
Today 12:07 EDT
Nothing about the recent past, present, or foreseeable future seems all that compelling.
Via
The Motley Fool
Gapping stocks in Tuesday's session
↗
Today 11:30 EDT
Via
Chartmill
Performance
YTD
-14.5%
-14.5%
1 Month
-25.1%
-25.1%
3 Month
-15.0%
-15.0%
6 Month
-19.4%
-19.4%
1 Year
-21.5%
-21.5%
More News
Read More
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Today 10:28 EDT
Via
MarketMinute
BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit
↗
Today 8:25 EDT
Via
Chartmill
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio
↗
January 16, 2026
Via
Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session.
↗
Today 9:30 EDT
Via
Chartmill
Why Did BNTX Stock Tumble 17% Pre-Market Today?
↗
Today 7:23 EDT
Via
Stocktwits
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Today 6:45 EDT
From
BioNTech SE
Via
GlobeNewswire
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
Today 6:33 EDT
From
BioNTech SE
Via
GlobeNewswire
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
March 06, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
March 05, 2026
Via
Finterra
Topics
Intellectual Property
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
February 24, 2026
From
BioNTech SE
Via
GlobeNewswire
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
February 11, 2026
Via
Finterra
Topics
Artificial Intelligence
Initial Public Offering
Intellectual Property
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
January 28, 2026
From
BioNTech SE
Via
GlobeNewswire
2 Biotech Stocks Set to Rebound in 2026
↗
January 27, 2026
Via
The Motley Fool
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
January 22, 2026
Via
MarketMinute
Topics
Intellectual Property
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
January 22, 2026
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
January 14, 2026
From
USA News Group
Via
GlobeNewswire
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It
↗
January 14, 2026
Via
Chartmill
Topics
Government
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
BioNTech SE
Via
GlobeNewswire
Frequently Asked Questions
Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 82.69
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 03/10/26 03:46 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.